evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

213 questions · 229 findings · 30 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 43 · 18.8%GRADE not reported 17 · 7.4%Very low 42 · 18.3%Low 67 · 29.3%Moderate 54 · 23.6%High 6 · 2.6%

Methotrexate vs placebo

Health‐related quality of life ‐ not reported · psoriatic arthritis

The review found no eligible studies for this question.

1 finding from 1 review

Methotrexate vs placebo

Change in radiographic progression ‐ not measured · psoriatic arthritis

The review found no eligible studies for this question.

1 finding from 1 review

Methotrexate vs placebo

SAEs · psoriatic arthritis

Methotrexate showed no clear difference in serious adverse events (SAEs) assessed by number of events compared with placebo (low certainty).

1 finding from 1 review

Methotrexate vs placebo

Withdrawals due to adverse events · psoriatic arthritis

Methotrexate showed no clear difference in withdrawals due to adverse events (WAEs) assessed by number of events compared with placebo (low certainty).

1 finding from 1 review

Methotrexate vs other DMARDs

Disease response (leflunomide) · psoriatic arthritis

It is very uncertain whether methotrexate changes disease response (leflunomide) compared with other DMARDs (very low certainty).

1 finding from 1 review

Methotrexate vs placebo

Failure to enter remission or possible remission at 16 weeks (Arora 1999) · adult patients with refractory Crohn's disease

Methotrexate showed no clear difference in failure to enter remission or possible remission at 16 weeks (Arora… compared with placebo (low certainty).

3 findings from 1 review

Methotrexate vs 6‐MP or azathioprine

Withdrawals due to adverse events · adult patients with refractory Crohn's disease

It is very uncertain whether methotrexate changes withdrawal due to adverse event (Oren 1997) compared with 6‐MP or azathioprine (very low certainty).

3 findings from 1 review

Methotrexate vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Failure to enter remission or possible remission at 16 weeks (Arora 1999) · adult patients with refractory Crohn's disease

It is very uncertain whether methotrexate changes failure to enter remission or possible remission at 30 weeks… compared with 5‐ASA (very low certainty).

1 finding from 1 review